A practical reference on Reference standard: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-18. Anything still debated is marked as such rather than presented as settled.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic PPARδ agonist | Not a steroid or a selective androgen receptor modulator. |
| Common synonyms | Cardarine, GW501516, GW-501516, endurobol | Names vary by supplier and literature source. |
| Appearance | White to off-white powder | Consistent with many small-molecule research chemicals. |
| Solubility | Low in water; soluble in DMSO and ethanol | Often prepared in organic solvent for laboratory work. |
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid and energy metabolism. |
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
A study of transgender Ontario residents aged 16 and over, published in 2016, found that half of them were reluctant to discuss transgender issues with their family doctor. A 2013–2014 nationwide study of young transgender and genderqueer Canadians found that a third of younger (ages 14–18) and half of the older (ages 19–25) respondents missed needed physical health care. Only 15 percent of respondents with a family doctor felt very comfortable discussing transgender issues with them. All Canadian provinces fund some sex reassignment surgeries, with New Brunswick being the last of the provinces to start insuring these procedures in 2016. Waiting times for surgeries can be lengthy, as few surgeons in the country provide them; a clinic in Montreal is the only one providing a full range of procedures. Insurance coverage is not generally provided for the transition-related procedures of facial feminization surgery, tracheal shave, or laser hair removal. And in January 2024, The Alberta government of Danielle Smith announced plans to ban gender affirming surgeries for minors under the age of 18 and hormones and puberty blockers for minors under the age of 16. According to the Canadian Pediatric Society, "Current evidence shows puberty blockers to be safe when used appropriately, and they remain an option to be considered within a wider view of the patient's mental and psychosocial health."
Endre Mester (1903–1984) was a Hungarian physician and pioneer of laser medicine, especially the use of low level laser therapy (LLLT). In 1967, only a few years after the first working laser was invented, he started his experiments with the effects of lasers on skin cancer. He is credited as the discoverer of positive biological effects of low power lasers, which have been advocated as alternative medicine for use in wound healing, smoking cessation, tuberculosis, temporomandibular joint disorders, and musculoskeletal conditions such as carpal tunnel syndrome, fibromyalgia, osteoarthritis, and rheumatoid arthritis. LLLT devices are popular and may bring about temporary relief of some types of pain. As of 2009, a summary from Quackwatch reported medical authorities found no reason to believe LLLT influence the course of any ailment or are more effective for pain control than other forms of heat delivery. Subsequent research has found LLLT may offer benefit in treating several health ailments, including rheumatoid arthritis, osteoarthritis, tendinopathy, and frozen shoulders.
=== LOCAL algorithm of Larget and Simon === The LOCAL algorithms offers a computational advantage over previous methods and demonstrates that a Bayesian approach is able to assess uncertainty computationally practical in larger trees. The LOCAL algorithm is an improvement of the GLOBAL algorithm presented in Mau, Newton and Larget (1999) in which all branch lengths are changed in every cycle. The LOCAL algorithms modifies the tree by selecting an internal branch of the tree at random. The nodes at the ends of this branch are each connected to two other branches. One of each pair is chosen at random. Imagine taking these three selected edges and stringing them like a clothesline from left to right, where the direction (left/right) is also selected at random. The two endpoints of the first branch selected will have a sub-tree hanging like a piece of clothing strung to the line. The algorithm proceeds by multiplying the three selected branches by a common random amount, akin to stretching or shrinking the clothesline. Finally the leftmost of the two hanging sub-trees is disconnected and reattached to the clothesline at a location selected uniformly at random. This would be the candidate tree. Suppose we began by selecting the internal branch with length
=== The catalytic protein === The main catalytic protein in telomerase is telomerase reverse transcriptase, 2627 amino acids long in humans. The protein consists of four conserved domains (RNA-Binding Domain (TRBD), fingers, palm and thumb), organized into a "right hand" ring configuration that shares common features with retroviral reverse transcriptases, viral RNA replicases and bacteriophage B-family DNA polymerases. TERT proteins from many eukaryotes have been sequenced.
When the IBD column compared to recently established PNIPAAm columns, electrostatic forces show remarkably higher retention ability of charged compounds than its hydrophilic predecessor. A single stationary phase can accomplish pharmaceutical separations based on hydrophobic interactions, hydrophilic interactions, and electrostatic interactions merely by adjusting the temperature (while adjusting pH to tweak the LCST).
Sources: en.wikipedia.org
"In order to avoid possible health risks, the German Federal Office for Radiation Protection recommends that you minimize your personal exposure to radiation through your own initiative." As of 2016, the EMF Guideline 2016 of EUROPAEM (European Academy For Environmental Medicine) on the prevention, diagnosis and treatment of EMF-related complaints and diseases applies.
=== Applied Radiation Corporation === In June 1960, High Voltage Engineering Corporation acquired Applied Radiation Corporation (ARCO) of Walnut Creek, California through a stock exchange. ARCO manufactured a line of linear accelerators with uses complementing those of HVEC's existing Van de Graaff accelerators. Applied Radiation was established as a separate subsidiary under its existing management, though its sales operations were integrated with HVEC's broader organization. The acquisition, however, would prove short-lived due to antitrust concerns. At the time, HVEC dominated the market for research accelerators, controlling an 80 percent share of orders. In April 1963, the Federal Trade Commission issued a consent decree requiring HVEC to divest itself of Applied Radiation Corporation. This forced divestiture reflected FTC concerns about concentration in the particle accelerator manufacturing industry, as both firms competed for research and industrial accelerator clients.
As an AAS, ethylestrenol is an agonist of the androgen receptor (AR), similarly to androgens like testosterone and dihydrotestosterone (DHT). It has low estrogenic activity (via aromatization into ethylestradiol following transformation into norethandrolone), strong progestogenic activity, and a high ratio of anabolic to androgenic activity, similarly to other nandrolone derivatives. Like other 17α-alkylated AAS, ethylestrenol has a risk of hepatotoxicity.
== Career == Wadden joined the University of Pennsylvania’s Department of Psychiatry as an instructor in 1981 and rose to full professor by 1994. From 1992 to 1993, he was Professor of Psychology and Director of Clinical Training at Syracuse University, where he also led the Center for Health and Behavior. Returning to Penn in 1994, he directed the Center for Weight and Eating Disorders until 2017. He was the first Albert J. Stunkard Professor in Psychiatry (2011–2021). He has also taught as Visiting Professor of Psychology at Haverford College (2013–2021) and Bryn Mawr College (2018–2019), offering courses on obesity and health psychology. In addition, he is Clinical Associate Professor at the Philadelphia College of Osteopathic Medicine. Wadden was president of The Obesity Society in 2005–2006 and has served as associate editor of its journal, Obesity (2010–2014; 2020–2025). He was also associate editor of Annals of Behavioral Medicine (1991–1993).
Chiral column chromatography is a variant of column chromatography that is employed for the separation of chiral compounds, i.e. enantiomers, in mixtures such as racemates or related compounds. The chiral stationary phase (CSP) is made of a support, usually silica based, on which a chiral reagent or a macromolecule with numerous chiral centers is bonded or immobilized. The chiral stationary phase can be prepared by attaching a chiral compound to the surface of an achiral support such as silica gel. For example, one class of the most commonly used chiral stationary phases both in liquid chromatography and supercritical fluid chromatography is based on oligosaccharides such as amylose, cellulose, or cyclodextrin (in particular with β-cyclodextrin, a seven sugar ring molecule) immobilized on silica gel. The principle can be also applied to the fabrication of Monolithic HPLC columns or Gas Chromatography columns. or Supercritical Fluid Chromatography columns.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.
It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.
No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.